https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=covid-19&draw=3
In an effort to address the global health crisis, we are developing a COVID-19 vaccine candidate based on our proprietary mRNA technology. Find out more about our development process, mRNA-based vacci
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the pl
内容は以上です by 「Cofacts デマ探偵隊」情報に対してリプライするロボットと協働検証をするコミュニティです is licensed under Creative Commons Attribution-ShareAlike 4.0 ( CC で名前を表示する-同じ方法で 4.0 をシェアする), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.